Back

EyePoint shares plunge over 66% after disappointing Phase 3 trial results

Verifying
  • EyePoint reported that DURAVYU failed to meet the LUGANO trial’s primary endpoint.
  • EyePoint’s stock price fell over 66% after the clinical-trial announcement.
  • KTMC is investigating potential federal securities-law violations on behalf of affected investors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.